森萱医药(830946) - 2023 Q1 - 季度财报

Financial Performance - Net profit attributable to shareholders for Q1 2023 was CNY 45,399,312.04, down 9.15% from CNY 49,972,953.24 in Q1 2022[9] - Operating revenue for Q1 2023 was CNY 175,152,565.78, a decrease of 4.08% compared to CNY 182,603,038.82 in the same period last year[9] - The net cash flow from operating activities decreased by 40.61% to CNY 24,748,327.96 from CNY 41,670,594.01 in the previous year[10] - Total operating revenue for Q1 2023 was CNY 175,152,565.78, a decrease from CNY 182,603,038.82 in Q1 2022, representing a decline of approximately 8.0%[75] - Net profit for Q1 2023 was CNY 47,662,270.56, down from CNY 53,340,658.13 in Q1 2022, reflecting a decrease of approximately 10.4%[76] - Earnings per share for Q1 2023 were CNY 0.1063, compared to CNY 0.1171 in Q1 2022, showing a decline of about 6.8%[76] Assets and Liabilities - Total assets as of March 31, 2023, reached CNY 1,316,040,144.93, an increase of 1.77% compared to the end of 2022[9] - The company's asset-liability ratio (consolidated) improved to 8.42% from 10.55% year-on-year[9] - The balance of accounts receivable increased by 276.28% to CNY 8,781,800 from the beginning of the year, mainly due to increased business settled by notes[11] - The balance of contract liabilities decreased by 52.14% to CNY 4,821,500, primarily due to a reduction in advance customer payments[11] - Total liabilities decreased to CNY 110,800,087.00 from CNY 136,386,510.76, indicating a decrease of approximately 18.7%[69] - The total equity attributable to shareholders increased to ¥1,132,562,063.11 from ¥1,086,641,028.20, marking a growth of approximately 4.2%[70] Cash Flow - Cash and cash equivalents decreased by CNY 1,611,400, with a net increase of cash and cash equivalents down 60.83% year-on-year[14] - The company reported a cash inflow from operating activities of CNY 114,578,823.47[19] - The net cash flow from operating activities for Q1 2023 was -2,620,049.16 CNY, compared to 154,984.76 CNY in Q1 2022, indicating a significant decline in operational cash generation[81] - Total cash inflow from operating activities in Q1 2023 was ¥140,961,929.11, compared to ¥147,707,932.11 in Q1 2022, a decline of approximately 4.6%[79] - Cash outflow for operating activities in Q1 2023 was ¥116,213,601.15, an increase from ¥106,037,338.10 in Q1 2022, representing an increase of about 9.9%[79] Shareholder Information - The total number of ordinary shares at the end of the period was 426,918,340, with 99.9561% being unrestricted shares[21] - The largest shareholder, Jinghua Pharmaceutical Group Co., Ltd., holds 72.3146% of the shares, totaling 308,724,340 shares[22] - The company has a stock price stabilization plan that will be activated if the stock price falls below the audited net asset value per share for 20 consecutive trading days[34] - The company plans to implement profit distribution or capital reserve conversion to stabilize stock prices if necessary, with a board meeting to be held within 5 trading days to discuss proposals[35] - Cash dividends will be distributed at a minimum of 10% of the annual distributable profit, with a cumulative minimum of 30% over any three consecutive years[48] Commitments and Compliance - The company has committed to a stable and continuous profit distribution policy, prioritizing cash dividends whenever possible[45] - The controlling shareholder has committed not to interfere with the company's management or harm its interests[43] - The company will comply with all relevant regulations regarding shareholding and changes, ensuring transparency in its operations[50] - The company guarantees the authenticity, accuracy, and completeness of its public offering application documents, and will bear legal responsibility for any false statements or omissions[54] - The company has pledged to hold a board or shareholder meeting within 10 working days to revise internal control systems to prevent participation in any fund pool business[62] Operational Efficiency - The company will enhance management efficiency and control costs to improve operational performance and profitability[41] - The company will establish a special account for the management of raised funds to ensure their proper use[42] - The company aims to accelerate the investment progress of fundraising projects to achieve expected benefits as soon as possible[42] - The company is focusing on research and development, with R&D expenses reported at CNY 5,774,630.02 in Q1 2022, down from CNY 8,037,579.41 in Q1 2021, suggesting a strategic shift in investment priorities[75]